PHOTO
Dubai - Medtronic, Inc. (NYSE: MDT), one of the world's largest medical technology companies headquartered in the US, introduced itsrecent innovations in interventional cardiology to the region's cardiologists and paramedical professionals at the 4thGulfPCR-GIM 2014 held in Dubai. The two-day event, held in December 2014, saw Medtronic unveiling its recent innovative advancements in CardioVascular therapies and an array of path-breaking solutions under the theme of 'Delivering more.'
GulfPCR-GIM is the region's premier event for interventional cardiologists and cathlab staff to share knowledge and experience on existing and new technologies towards improving cardiovascular care. The interactive course programme also reaches out to a wider international audience, to share and learn from the expertise in the Gulf and Middle East, and to stimulate regional projects.
"GulfPCR is a leading forum and one of the most important congresses in Interventional cardiology in the region. Year after year, we work on demonstrating its importance to the medical community by presenting the cutting-edge therapies we have access to. We have achieved amazing growth, and still continue to do so. We are certainly looking forward to achieving more success moving forward, to allow us to reach more patients in need of cardiovascular intervention," said Dr. Ibrahim Al Rashdan, Consultant Interventional cardiologist at Chest Disease Hospital in Kuwait and GulfPCR-GIM Course Director.
Reaffirming its commitment to the region's healthcare industry, Medtronic also organised roadshows and workshops led by experts from the US as part of GulfPCR-GIM in addition to introducing its innovations at the event.
"For example, Medtronic's third generation Resolute Onyx™ represents multiple innovations to specifically address the need for continued procedural efficiency and ease of use. It is designed to be the most deliverable Drug Eluting Stent (DES) to date, featuring Core Wire Technology that enables thinner struts with increased radiopacity (i.e. enhanced visibility during procedures) and no compromise to radial or longitudinal strength. Resolute Onyx's broad size matrix helps optimize the treatment of complex clinical scenarios with the proven long-term safety and efficacy of the Resolute platform" said Ghada Farah, Business Director, Coronary & RDN for Medtronic in Middle East, Africa, Central Asia and Turkey.
The Medtronic range of innovations at GulfPCR-GIM also included its next generation CoreValveEvolutR TAVI System, a self-expanding device with the option to recapture the valve back into the catheter and reposition it for an optimum placement. The system offersadvanced deliverability and improved valve performance.
"The CoreValve EvolutR Transcatheter Aortic Valve System enables replacing a diseased aortic valve through a tansfemoral approach procedure with improved accuracy and optimum hemodynamic performance. It also offers a new InLine Sheath that significantly reduces the profile to the lowest in the market (14 F equivalent to true 18F Inner & Outer Diameter). A smaller profile size is believed to improve access and bring down the risk of major cardiovascular complications", explained Abed Saoud, Business Director, Structural Heart at Medtronic in Middle East,Africa& Central Asia.
Also featuring in the Medtronic innovation series at GulfPCR-GIM was the REVEAL LINQ Insertable Cardiac Monitor (ICM), currently the smallest implantable cardiac monitor available for patients. Approximately one-third the size of an AAA battery in size (i.e. more than 80 per cent smaller than other ICMs) the device is part of a powerful system that allows physicians to continuously and wirelessly monitor a patient's heart for up to three years, with 20 per cent more data memory than its larger predecessor, Reveal XT.Placed just beneath the skin through a small incision of less than one centimeter in the upper left side of the chest, the ICM is nearly invisible to the naked eye once inserted.
Another innovative product that Medtronic is showcasing at GulfPCR-GIM this year is the world's smallest pacemaker to date: the Micra Transcatheter Pacing System (TPS). At one-tenth the size of a conventional pacemaker, and comparable in size to a large vitamin, the Micra TPS is delivered directly into the heart through a catheter inserted in the femoral vein. Once positioned, the pacemaker is securely attached to the heart wall and can be repositioned if needed. The miniature device does not require the use of wires, known as "leads," to connect to the heart. Attached to the heart via small tines, the pacemaker delivers electrical impulses that pace the heart through an electrode at the end of the device.
"In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. We are committed to offering physicians and patients improved outcomes by bringing the latest innovations to Middle East and Africa as soon as they are launched globally", said Mohammed Barhoumi, Vice President, CardioVascular Group and CRHF for Medtronic in Middle East, Africa, Central Asia and Turkey.
In addition to product and therapy innovation, Medtronic presented to GulfPCR participants its newly formed entity in the region entitled Medtronic Hospital Solutions, which is focused on providing more than just Medtronic devices by broadening the offer to include managed catheterization laboratory services and efficiencies to help hospitals address their investment challenges and achieve better economic value and sustainability, as well as allow better patient access.
-Ends-
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world. Every 3 seconds, Medtronic improves another person's life.Medtronic's headquarters for Middle East and Africa is in Dubai, supporting patients in the region for almost twenty years andtreating nearly 40 medical conditions in cardiac and vascular diseases, diabetes, and neurological and spinal conditions.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
For more information and media enquiries please contact:
Prem A. Ramachandran,
Managing Director
White Water Public Relations
GSM: 0097150-4537253
PO. Box 18936, Dubai, UAE
Email: prem@whitewaterpr.com
www.whitewaterpr.com
© Press Release 2015
